These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 31481612)

  • 1. Decreased humoral immunity to mumps in young adults immunized with MMR vaccine in childhood.
    Rasheed MAU; Hickman CJ; McGrew M; Sowers SB; Mercader S; Hopkins A; Grimes V; Yu T; Wrammert J; Mulligan MJ; Bellini WJ; Rota PA; Orenstein WA; Ahmed R; Edupuganti S
    Proc Natl Acad Sci U S A; 2019 Sep; 116(38):19071-19076. PubMed ID: 31481612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age.
    Haralambieva IH; Ovsyannikova IG; Kennedy RB; Goergen KM; Grill DE; Chen MH; Hao L; Icenogle J; Poland GA
    Vaccine; 2020 Jan; 38(5):1249-1257. PubMed ID: 31732325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mumps-specific cross-neutralization by MMR vaccine-induced antibodies predicts protection against mumps virus infection.
    Gouma S; Ten Hulscher HI; Schurink-van 't Klooster TM; de Melker HE; Boland GJ; Kaaijk P; van Els CACM; Koopmans MPG; van Binnendijk RS
    Vaccine; 2016 Jul; 34(35):4166-4171. PubMed ID: 27372154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Use of an Endpoint Titration Assay To Characterize Mumps IgG Avidity following Measles, Mumps, and Rubella Vaccination and Wild-Type Mumps Infection.
    Mercader S; McGrew M; Sowers SB; Williams NJ; Bellini WJ; Hickman CJ
    mSphere; 2018 Sep; 3(5):. PubMed ID: 30209129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy.
    Madi N; Altawalah H; Alfouzan W; Al-Nakib W; Al-Roumi E; Jeragh A
    J Med Virol; 2020 Aug; 92(8):963-970. PubMed ID: 31919861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines.
    Schwarzer S; Reibel S; Lang AB; Struck MM; Finkel B; Gerike E; Tischer A; Gassner M; Glück R; Stück B; Cryz SJ
    Vaccine; 1998; 16(2-3):298-304. PubMed ID: 9607046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.
    Kontio M; Palmu AA; Syrjänen RK; Lahdenkari M; Ruokokoski E; Davidkin I; Vaarala O; Melin M
    J Infect Dis; 2016 Jun; 213(12):2005-13. PubMed ID: 26908733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Third Dose of Measles-Mumps-Rubella Vaccine to Improve Immunity Against Mumps in Young Adults.
    Kaaijk P; Wijmenga-Monsuur AJ; van Houten MA; Veldhuijzen IK; Ten Hulscher HI; Kerkhof J; van der Klis FR; van Binnendijk RS
    J Infect Dis; 2020 Mar; 221(6):902-909. PubMed ID: 31112277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
    Feiterna-Sperling C; Brönnimann R; Tischer A; Stettler P; Durrer P; Gaedicke G
    Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak.
    Rubin SA; Qi L; Audet SA; Sullivan B; Carbone KM; Bellini WJ; Rota PA; Sirota L; Beeler J
    J Infect Dis; 2008 Aug; 198(4):508-15. PubMed ID: 18558869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults.
    Fiebelkorn AP; Coleman LA; Belongia EA; Freeman SK; York D; Bi D; Kulkarni A; Audet S; Mercader S; McGrew M; Hickman CJ; Bellini WJ; Shivakoti R; Griffin DE; Beeler J
    J Infect Dis; 2016 Apr; 213(7):1115-23. PubMed ID: 26597262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sera from different age cohorts in Belgium show limited cross-neutralization between the mumps vaccine and outbreak strains.
    Vermeire T; Barbezange C; Francart A; Hamouda A; Litzroth A; Hutse V; Martens L; Vandermarliere E; Van Gucht S
    Clin Microbiol Infect; 2019 Jul; 25(7):907.e1-907.e6. PubMed ID: 30502489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential durability of immune responses to measles and mumps following MMR vaccination.
    Kennedy RB; Ovsyannikova IG; Thomas A; Larrabee BR; Rubin S; Poland GA
    Vaccine; 2019 Mar; 37(13):1775-1784. PubMed ID: 30797639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study.
    Abu-Elyazeed R; Jennings W; Severance R; Noss M; Caplanusi A; Povey M; Henry O
    Hum Vaccin Immunother; 2018; 14(11):2624-2631. PubMed ID: 29902133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
    Carryn S; Feyssaguet M; Povey M; Di Paolo E
    Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroprevalences of Specific IgG Antibodies to Measles, Mumps, and Rubella in Korean Infants.
    Cho HK; Lee H; Kim HW; Kim SS; Kang HJ; Kim IT; Kim KH
    J Korean Med Sci; 2016 Dec; 31(12):1957-1962. PubMed ID: 27822935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of antibodies against measles, mumps and rubella in the childhood population in Singapore, 2008-2010.
    Ang LW; Lai FY; Tey SH; Cutter J; James L; Goh KT
    Epidemiol Infect; 2013 Aug; 141(8):1721-30. PubMed ID: 22999024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ; Fathpour GR; Parsaei MR; Ajami A; Khalilian AR; Shojaei J; Saffar H
    J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
    He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
    [No Abstract]   [Full Text] [Related]  

  • 20. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
    Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.